Should You Buy Moderna Before May 12? [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
But as demand for the vaccine declined, Moderna stock followed. Investors are worried about future growth since the vaccine is the biotech's only commercialized product. But things may be about to turn around for Moderna. The biotech company aims to bring as many as 15 new products to market over the next five years and has the late-stage pipeline to support such aspirations. The commercialization of Moderna's next product may be right around the corner if all goes well during the regulatory review stage. The U.S. Food and Drug Administration (FDA) is set to issue a decision on the company's respiratory syncytial virus (RSV) vaccine candidate by May 12. Should you buy shares of this ambitious biotech company before then? Rival RSV vaccines Here's more information about this potential product. If approved, it won't be the first RSV vaccine to hit the market. GSK and Pfizer both won approval for their RSV vaccines last year, and they're the only such products out there right now
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Analysts Are Updating Their Moderna, Inc. (NASDAQ:MRNA) Estimates After Its First-Quarter Results [Yahoo! Finance]Yahoo! Finance
- Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $91.00 to $106.00. They now have a "hold" rating on the stock.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Royal Bank of Canada from $125.00 to $135.00. They now have an "outperform" rating on the stock.MarketBeat
- Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $142.00 to $163.00. They now have an "outperform" rating on the stock.MarketBeat
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 5/3/24 - Form 4
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- MRNA's page on the SEC website